GLP-1 provider safety check
The GLP-1 boom brought a wave of sketchy sellers, and in 2026 the FDA stepped up enforcement against unsafe operators. Before you hand over money or inject anything, check that a program clears the basics.
Safety signal
Strong
Prescription required
A licensed prescriber reviews your case (online visit with licensed doctors).
Licensed clinicians
US-licensed doctors
Accredited / licensed pharmacy
503A pharmacies; LegitScript-certified
LegitScript-certified (stated)
Publicly states LegitScript certification — a strong trust signal.
Transparent about compounding
Uses compounded medication (not an FDA-approved finished product) — the pharmacy's legitimacy matters.
This check reflects provider-reported information and general safety criteria — it is not an FDA audit or an endorsement. Always verify licensing and certification directly with the provider and your state board of pharmacy before enrolling.
Red flags — walk away
- Selling GLP-1 with no prescription or medical review
- Products labeled "research use only" or "not for human consumption"
- Unlabeled vials, no dosing instructions, or no clinician to contact
- No verifiable, state-licensed pharmacy behind the medication
- Prices that seem too good to be true with no accreditation
- Pressure to buy large quantities up front with no clinical follow-up
Green flags — signs of a legitimate program
- A licensed prescriber reviews your medical history
- A state-licensed pharmacy fills the prescription (LegitScript certification is a strong sign)
- Clear, written dosing instructions and a way to reach a clinician
- Transparent about whether the medication is compounded or branded
- Honest medical screening that can turn you away if GLP-1 isn't safe for you
How we assess safety
Our check looks at the factors regulators and pharmacy boards care about: whether a licensed prescriber is genuinely involved, whether a state-licensed and ideally LegitScript-certified pharmacy fills the medication, and whether the program is transparent about compounded vs branded products. It reflects provider-reported information — not an FDA audit — so always verify directly. The FDA has specifically warned about the risks of unapproved and improperly compounded GLP-1 products, including dosing errors and adverse events.
Sources & references
Clinical figures on this page trace to peer-reviewed trials and official regulators. We link the primary record so you can verify it yourself.
- 1.U.S. Food & Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.RegulatoryU.S. Food & Drug Administration
- 2.
- 3.U.S. Food & Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize.RegulatoryU.S. Food & Drug Administration